Pawlotsky Jean-Michel, Gish Robert G
Department of Virology, INSERM U635, Henri Mondor Hospital, University of Paris, Créteil, France.
Antivir Ther. 2006;11(4):397-408.
Although pegylated interferon-alpha plus ribavirin has become the standard for treating chronic hepatitis C virus infection, a substantial number of patients do not tolerate therapy and require dose reduction or discontinuation, or do not respond to this combination therapy. Thus, new therapeutic options are needed. An increased knowledge of the hepatitis C virus and an understanding of its replication cycle, as well as advances in biotechnology, have stimulated the development of numerous new antiviral treatments for patients with hepatitis C virus infection. This review focuses on four classes of new agents: new interferons, ribavirin-like molecules, specific small-molecule hepatitis C virus inhibitors and new immune therapies, with particular emphasis on medications in the later stages of development.
尽管聚乙二醇化干扰素-α联合利巴韦林已成为治疗慢性丙型肝炎病毒感染的标准疗法，但仍有相当数量的患者无法耐受该治疗，需要减少剂量或停药，或者对这种联合治疗无反应。因此，需要新的治疗选择。对丙型肝炎病毒了解的增加及其复制周期的认识，以及生物技术的进步，促使了众多针对丙型肝炎病毒感染患者的新型抗病毒治疗方法的开发。本综述重点关注四类新型药物：新型干扰素、利巴韦林样分子、特异性小分子丙型肝炎病毒抑制剂和新型免疫疗法，特别强调处于研发后期的药物。
